Therefore, the purpose of this comprehensive review is to examine the use of IL-2 at different dosing regimens in metastatic renal cell carcinoma and melanoma to determine whether there is a target dose that produces optimal patient outcome with minimal toxicity. The gene discussed is IL2; the disease is melanoma.